Business Context and Reporting Period
Company: Viridian Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 8, 2021
Event: Filing of a new shelf Registration Statement on Form S-3 to replace an existing registration statement.
Key Financial Metrics
- Cash and Investments: Approximately $213.8 million in cash, cash equivalents, and short-term investments as of September 30, 2021.
- Capital Raised (Prior Shelf): Approximately $149 million in aggregate gross proceeds issued under the previous Form S-3 (File No. 333-237413).
- Debt and Margins: The filing text does not provide specific values for debt, revenue, profit, margins, or cash flow for the current period.
Material Changes and New Offerings
On November 8, 2021, the Company filed a new shelf Registration Statement on Form S-3 to replace the existing one. The new registration includes:
- Base Prospectus: Authorization to offer common stock, preferred stock, debt securities, warrants, and units in an aggregate amount of up to $350,000,000.
- At-the-Market Offering: Authorization to sell up to $75,000,000 of common stock under a Sale Agreement. The Company is not obligated to make any sales under this agreement.
Outlook and Management Commentary
Management expects that current resources (approximately $213.8 million as of September 30, 2021) will be sufficient to fund operations into 2024. The filing explicitly states it does not constitute an offer to sell securities.
Investor Verification Checklist
- Verify the effectiveness date of the new Form S-3 Registration Statement with the SEC.
- Confirm the specific terms of the "Sale Agreement" referenced for the at-the-market offering.
- Review the most recent Form 10-Q (filed November 5, 2021) for detailed cash burn rates and operational expenses.
- Monitor future filings for actual sales executed under the new $350 million shelf capacity.